This suggests that targeting PHLDA1+ mCAFs, either alone or in combination with interventions aimed at other CAF subtypes, could provide a more comprehensive strategy for disrupting tumor–stroma interactions and improving therapeutic outcomes in pancreatic cancer. This evidence concerns the gene PHLDA1 and neoplasm.